{
"indication": {
"drug": "Avelumab (Bavencio)",
"disease": "Metastatic/Advanced Urothelial Carcinoma",
"line": "First-line",
"setting": "After platinum chemotherapy without progression",
"last_updated": "2025-01-17",
"updated_by": "EMD Serono Competitive Intelligence Tool"
},
"direct_competitors": [
{
"drug": "Enfortumab vedotin + Pembrolizumab",
"line_of_therapy": "1L",
"company": "Astellas/Seagen/Merck",
"moa": "Nectin-4 ADC + PD-1 inhibitor",
"trials": "EV-302/KEYNOTE-A39 (median OS 34 months vs 16.1 months for chemo)",
"threat_level": "HIGH",
"rationale": "New 1L standard of care with unprecedented survival benefit, FDA approved Dec 2023",
"keywords": ["enfortumab", "vedotin", "padcev", "pembrolizumab", "keytruda", "pembro", "EV-302", "EV302", "EV 302", "KEYNOTE-A39", "KEYNOTE A39", "A39", "EV+P", "EV+pembro", "EV-P", "EVP", "UNITE", "EV-103", "EV103", "KEYNOTE-905"]
},
{
"drug": "Durvalumab + chemotherapy (perioperative)",
"line_of_therapy": "1L",
"company": "AstraZeneca",
"moa": "PD-L1 inhibitor + chemotherapy",
"trials": "NIAGARA (EFS HR 0.68, OS HR 0.75)",
"threat_level": "MEDIUM",
"rationale": "Perioperative approach for cisplatin-eligible MIBC patients, FDA PDUFA Q2 2025",
"keywords": ["durvalumab", "imfinzi", "NIAGARA", "perioperative", "neoadjuvant"]
},
{
"drug": "Nivolumab + gemcitabine-cisplatin",
"line_of_therapy": "1L",
"company": "Bristol Myers Squibb",
"moa": "PD-1 inhibitor + chemotherapy",
"trials": "CheckMate-901 (OS HR 0.78 vs chemo)",
"threat_level": "MEDIUM",
"rationale": "Alternative 1L option for cisplatin-eligible patients, less effective than EV+P",
"keywords": ["nivolumab", "opdivo", "CheckMate-901", "gemcitabine", "cisplatin"]
}
],
"key_biomarkers": [
{
"biomarker": "PD-L1 expression",
"clinical_utility": "Historical predictor of ICI response, less relevant with current combinations",
"prevalence": "~50% in urothelial cancer",
"keywords": ["PD-L1", "CPS", "combined positive score", "tumor proportion score"]
},
{
"biomarker": "FGFR3/2 alterations",
"clinical_utility": "Predictor for erdafitinib response",
"prevalence": "20% overall, 36% in upper tract",
"keywords": ["FGFR3", "FGFR2", "mutations", "fusions", "alterations"]
},
{
"biomarker": "Nectin-4 expression",
"clinical_utility": "Target for enfortumab vedotin, ubiquitously expressed",
"prevalence": ">90%",
"keywords": ["nectin-4", "nectin", "PVRL4", "enfortumab target"]
}
]